nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—CYP1A1—Dacarbazine—sarcoma	0.133	0.366	CbGbCtD
Sulindac—PTGS2—Etoposide—sarcoma	0.0769	0.212	CbGbCtD
Sulindac—PTGS1—Etoposide—sarcoma	0.0649	0.179	CbGbCtD
Sulindac—CYP1A2—Dacarbazine—sarcoma	0.0593	0.163	CbGbCtD
Sulindac—CYP1A2—Etoposide—sarcoma	0.029	0.0799	CbGbCtD
Sulindac—AKR1B1—sciatic nerve—sarcoma	0.0266	0.147	CbGeAlD
Sulindac—MAPK3—periosteum—sarcoma	0.0133	0.0737	CbGeAlD
Sulindac—PTGDR2—hematopoietic system—sarcoma	0.00625	0.0346	CbGeAlD
Sulindac—AKR1B1—mammary gland—sarcoma	0.00545	0.0302	CbGeAlD
Sulindac—MAPK3—endothelium—sarcoma	0.0049	0.0272	CbGeAlD
Sulindac—PPARD—mammary gland—sarcoma	0.00428	0.0238	CbGeAlD
Sulindac—PTGDR2—tendon—sarcoma	0.00413	0.0229	CbGeAlD
Sulindac—MAPK3—mammary gland—sarcoma	0.00395	0.0219	CbGeAlD
Sulindac—AKR1B1—myometrium—sarcoma	0.00387	0.0214	CbGeAlD
Sulindac—AKR1B1—embryo—sarcoma	0.00372	0.0206	CbGeAlD
Sulindac—AKR1B1—seminal vesicle—sarcoma	0.00349	0.0194	CbGeAlD
Sulindac—PTGS2—periosteum—sarcoma	0.00345	0.0191	CbGeAlD
Sulindac—AKR1B1—hematopoietic system—sarcoma	0.00332	0.0184	CbGeAlD
Sulindac—AKR1B1—connective tissue—sarcoma	0.0032	0.0177	CbGeAlD
Sulindac—AKR1B1—smooth muscle tissue—sarcoma	0.00292	0.0162	CbGeAlD
Sulindac—MAPK3—myometrium—sarcoma	0.0028	0.0155	CbGeAlD
Sulindac—PTGS2—leg—sarcoma	0.00275	0.0153	CbGeAlD
Sulindac—MAPK3—embryo—sarcoma	0.0027	0.0149	CbGeAlD
Sulindac—PPARD—hematopoietic system—sarcoma	0.00261	0.0145	CbGeAlD
Sulindac—MAPK3—seminal vesicle—sarcoma	0.00253	0.014	CbGeAlD
Sulindac—AKR1B1—cardiac atrium—sarcoma	0.00252	0.014	CbGeAlD
Sulindac—AKR1B1—uterus—sarcoma	0.00251	0.0139	CbGeAlD
Sulindac—PTGS2—hindlimb—sarcoma	0.00246	0.0136	CbGeAlD
Sulindac—PTGS2—cartilage tissue—sarcoma	0.00242	0.0134	CbGeAlD
Sulindac—MAPK3—hematopoietic system—sarcoma	0.00241	0.0133	CbGeAlD
Sulindac—AKR1B1—lymphoid tissue—sarcoma	0.00234	0.013	CbGeAlD
Sulindac—MAPK3—connective tissue—sarcoma	0.00232	0.0128	CbGeAlD
Sulindac—AKR1B1—tendon—sarcoma	0.0022	0.0122	CbGeAlD
Sulindac—AKR1B1—bone marrow—sarcoma	0.00213	0.0118	CbGeAlD
Sulindac—MAPK3—smooth muscle tissue—sarcoma	0.00212	0.0117	CbGeAlD
Sulindac—PTGS2—appendage—sarcoma	0.00211	0.0117	CbGeAlD
Sulindac—MAPK3—skin of body—sarcoma	0.00209	0.0116	CbGeAlD
Sulindac—ALB—mammary gland—sarcoma	0.00188	0.0104	CbGeAlD
Sulindac—PPARD—lymphoid tissue—sarcoma	0.00184	0.0102	CbGeAlD
Sulindac—MAPK3—cardiac atrium—sarcoma	0.00183	0.0101	CbGeAlD
Sulindac—AKR1B1—testis—sarcoma	0.00182	0.0101	CbGeAlD
Sulindac—MAPK3—uterus—sarcoma	0.00182	0.0101	CbGeAlD
Sulindac—PPARD—tendon—sarcoma	0.00173	0.00958	CbGeAlD
Sulindac—AKR1B1—liver—sarcoma	0.00172	0.00953	CbGeAlD
Sulindac—MAPK3—lymphoid tissue—sarcoma	0.00169	0.00939	CbGeAlD
Sulindac—MAPK3—tendon—sarcoma	0.00159	0.00883	CbGeAlD
Sulindac—MAPK3—bone marrow—sarcoma	0.00154	0.00855	CbGeAlD
Sulindac—PPARD—testis—sarcoma	0.00143	0.00793	CbGeAlD
Sulindac—PPARD—liver—sarcoma	0.00135	0.0075	CbGeAlD
Sulindac—PTGS1—endothelium—sarcoma	0.00133	0.00738	CbGeAlD
Sulindac—MAPK3—testis—sarcoma	0.00132	0.00731	CbGeAlD
Sulindac—AKR1B1—lymph node—sarcoma	0.00132	0.00731	CbGeAlD
Sulindac—PTGS2—endothelium—sarcoma	0.00127	0.00706	CbGeAlD
Sulindac—MAPK3—liver—sarcoma	0.00125	0.00691	CbGeAlD
Sulindac—PPARD—lymph node—sarcoma	0.00104	0.00575	CbGeAlD
Sulindac—MAPK3—lymph node—sarcoma	0.000956	0.0053	CbGeAlD
Sulindac—CYP1A2—hematopoietic system—sarcoma	0.000755	0.00418	CbGeAlD
Sulindac—CYP1A1—hematopoietic system—sarcoma	0.000744	0.00413	CbGeAlD
Sulindac—PTGS2—myometrium—sarcoma	0.000728	0.00404	CbGeAlD
Sulindac—PTGS2—embryo—sarcoma	0.0007	0.00388	CbGeAlD
Sulindac—PTGS1—seminal vesicle—sarcoma	0.000688	0.00381	CbGeAlD
Sulindac—PTGS2—seminal vesicle—sarcoma	0.000658	0.00365	CbGeAlD
Sulindac—PTGS1—hematopoietic system—sarcoma	0.000654	0.00362	CbGeAlD
Sulindac—CYP1A1—skin of body—sarcoma	0.000647	0.00359	CbGeAlD
Sulindac—PTGS1—connective tissue—sarcoma	0.00063	0.00349	CbGeAlD
Sulindac—ALB—testis—sarcoma	0.000629	0.00349	CbGeAlD
Sulindac—PTGS2—hematopoietic system—sarcoma	0.000625	0.00346	CbGeAlD
Sulindac—PTGS2—connective tissue—sarcoma	0.000602	0.00334	CbGeAlD
Sulindac—ALB—liver—sarcoma	0.000594	0.0033	CbGeAlD
Sulindac—PTGS1—smooth muscle tissue—sarcoma	0.000576	0.00319	CbGeAlD
Sulindac—PTGS1—skin of body—sarcoma	0.000568	0.00315	CbGeAlD
Sulindac—CYP1A1—cardiac atrium—sarcoma	0.000565	0.00313	CbGeAlD
Sulindac—CYP1A1—uterus—sarcoma	0.000562	0.00312	CbGeAlD
Sulindac—PTGS2—smooth muscle tissue—sarcoma	0.00055	0.00305	CbGeAlD
Sulindac—PTGS2—skin of body—sarcoma	0.000543	0.00301	CbGeAlD
Sulindac—PTGS1—cardiac atrium—sarcoma	0.000496	0.00275	CbGeAlD
Sulindac—PTGS1—uterus—sarcoma	0.000494	0.00274	CbGeAlD
Sulindac—PTGS2—uterus—sarcoma	0.000472	0.00262	CbGeAlD
Sulindac—ALB—lymph node—sarcoma	0.000456	0.00253	CbGeAlD
Sulindac—PTGS2—lymphoid tissue—sarcoma	0.00044	0.00244	CbGeAlD
Sulindac—PTGS1—tendon—sarcoma	0.000433	0.0024	CbGeAlD
Sulindac—PTGS2—tendon—sarcoma	0.000414	0.00229	CbGeAlD
Sulindac—PTGS2—bone marrow—sarcoma	0.000401	0.00222	CbGeAlD
Sulindac—CYP1A2—liver—sarcoma	0.000391	0.00217	CbGeAlD
Sulindac—CYP1A1—liver—sarcoma	0.000386	0.00214	CbGeAlD
Sulindac—Insomnia—Vincristine—sarcoma	0.000371	0.00184	CcSEcCtD
Sulindac—Renal impairment—Doxorubicin—sarcoma	0.000369	0.00183	CcSEcCtD
Sulindac—Paraesthesia—Vincristine—sarcoma	0.000369	0.00183	CcSEcCtD
Sulindac—Urticaria—Thiotepa—sarcoma	0.000368	0.00182	CcSEcCtD
Sulindac—Malaise—Etoposide—sarcoma	0.000367	0.00182	CcSEcCtD
Sulindac—Vertigo—Etoposide—sarcoma	0.000366	0.00182	CcSEcCtD
Sulindac—Body temperature increased—Thiotepa—sarcoma	0.000366	0.00181	CcSEcCtD
Sulindac—Leukopenia—Etoposide—sarcoma	0.000365	0.00181	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000364	0.00181	CcSEcCtD
Sulindac—Purpura—Doxorubicin—sarcoma	0.000364	0.00181	CcSEcCtD
Sulindac—Body temperature increased—Dactinomycin—sarcoma	0.000363	0.0018	CcSEcCtD
Sulindac—Paraesthesia—Mitoxantrone—sarcoma	0.000359	0.00178	CcSEcCtD
Sulindac—PTGS1—testis—sarcoma	0.000358	0.00199	CbGeAlD
Sulindac—Loss of consciousness—Etoposide—sarcoma	0.000358	0.00178	CcSEcCtD
Sulindac—Decreased appetite—Vincristine—sarcoma	0.000357	0.00177	CcSEcCtD
Sulindac—Dyspnoea—Mitoxantrone—sarcoma	0.000356	0.00177	CcSEcCtD
Sulindac—Somnolence—Mitoxantrone—sarcoma	0.000355	0.00176	CcSEcCtD
Sulindac—Fatigue—Vincristine—sarcoma	0.000354	0.00175	CcSEcCtD
Sulindac—Convulsion—Etoposide—sarcoma	0.000353	0.00175	CcSEcCtD
Sulindac—Dyspepsia—Mitoxantrone—sarcoma	0.000352	0.00175	CcSEcCtD
Sulindac—Hypertension—Etoposide—sarcoma	0.000352	0.00174	CcSEcCtD
Sulindac—Constipation—Vincristine—sarcoma	0.000351	0.00174	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.000351	0.00174	CcSEcCtD
Sulindac—Decreased appetite—Mitoxantrone—sarcoma	0.000348	0.00172	CcSEcCtD
Sulindac—Chest pain—Etoposide—sarcoma	0.000347	0.00172	CcSEcCtD
Sulindac—Fatigue—Mitoxantrone—sarcoma	0.000345	0.00171	CcSEcCtD
Sulindac—Discomfort—Etoposide—sarcoma	0.000343	0.0017	CcSEcCtD
Sulindac—Constipation—Mitoxantrone—sarcoma	0.000342	0.0017	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000342	0.00169	CcSEcCtD
Sulindac—Hypersensitivity—Thiotepa—sarcoma	0.000341	0.00169	CcSEcCtD
Sulindac—Hypersensitivity—Dactinomycin—sarcoma	0.000339	0.00168	CcSEcCtD
Sulindac—Gastrointestinal pain—Vincristine—sarcoma	0.000336	0.00166	CcSEcCtD
Sulindac—Gastritis—Epirubicin—sarcoma	0.000336	0.00166	CcSEcCtD
Sulindac—Muscular weakness—Epirubicin—sarcoma	0.000335	0.00166	CcSEcCtD
Sulindac—Anaphylactic shock—Etoposide—sarcoma	0.000333	0.00165	CcSEcCtD
Sulindac—Asthenia—Thiotepa—sarcoma	0.000332	0.00165	CcSEcCtD
Sulindac—Asthenia—Dactinomycin—sarcoma	0.00033	0.00163	CcSEcCtD
Sulindac—Feeling abnormal—Mitoxantrone—sarcoma	0.000329	0.00163	CcSEcCtD
Sulindac—Pruritus—Thiotepa—sarcoma	0.000328	0.00162	CcSEcCtD
Sulindac—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000327	0.00162	CcSEcCtD
Sulindac—Thrombocytopenia—Etoposide—sarcoma	0.000326	0.00161	CcSEcCtD
Sulindac—Tachycardia—Etoposide—sarcoma	0.000325	0.00161	CcSEcCtD
Sulindac—Eosinophilia—Epirubicin—sarcoma	0.000325	0.00161	CcSEcCtD
Sulindac—Body temperature increased—Vincristine—sarcoma	0.000325	0.00161	CcSEcCtD
Sulindac—PTGS2—liver—sarcoma	0.000324	0.0018	CbGeAlD
Sulindac—Hyperhidrosis—Etoposide—sarcoma	0.000322	0.00159	CcSEcCtD
Sulindac—Pancreatitis—Epirubicin—sarcoma	0.000321	0.00159	CcSEcCtD
Sulindac—Urticaria—Mitoxantrone—sarcoma	0.000318	0.00157	CcSEcCtD
Sulindac—Anorexia—Etoposide—sarcoma	0.000317	0.00157	CcSEcCtD
Sulindac—Diarrhoea—Thiotepa—sarcoma	0.000317	0.00157	CcSEcCtD
Sulindac—Body temperature increased—Mitoxantrone—sarcoma	0.000316	0.00157	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000316	0.00157	CcSEcCtD
Sulindac—Diarrhoea—Dactinomycin—sarcoma	0.000314	0.00156	CcSEcCtD
Sulindac—Pancytopenia—Epirubicin—sarcoma	0.000311	0.00154	CcSEcCtD
Sulindac—Hypotension—Etoposide—sarcoma	0.000311	0.00154	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—sarcoma	0.000311	0.00154	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—sarcoma	0.00031	0.00153	CcSEcCtD
Sulindac—Dysuria—Epirubicin—sarcoma	0.000307	0.00152	CcSEcCtD
Sulindac—Neutropenia—Epirubicin—sarcoma	0.000307	0.00152	CcSEcCtD
Sulindac—Dizziness—Thiotepa—sarcoma	0.000306	0.00152	CcSEcCtD
Sulindac—Hypersensitivity—Vincristine—sarcoma	0.000302	0.0015	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—sarcoma	0.0003	0.00149	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—sarcoma	0.000299	0.00148	CcSEcCtD
Sulindac—Paraesthesia—Etoposide—sarcoma	0.000299	0.00148	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—sarcoma	0.000297	0.00147	CcSEcCtD
Sulindac—Dyspnoea—Etoposide—sarcoma	0.000297	0.00147	CcSEcCtD
Sulindac—Hyperglycaemia—Epirubicin—sarcoma	0.000296	0.00147	CcSEcCtD
Sulindac—Somnolence—Etoposide—sarcoma	0.000296	0.00147	CcSEcCtD
Sulindac—CYP1A1—lymph node—sarcoma	0.000296	0.00164	CbGeAlD
Sulindac—Hypersensitivity—Mitoxantrone—sarcoma	0.000295	0.00146	CcSEcCtD
Sulindac—Asthenia—Vincristine—sarcoma	0.000295	0.00146	CcSEcCtD
Sulindac—Vomiting—Thiotepa—sarcoma	0.000294	0.00146	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—sarcoma	0.000294	0.00146	CcSEcCtD
Sulindac—Vomiting—Dactinomycin—sarcoma	0.000292	0.00145	CcSEcCtD
Sulindac—Rash—Thiotepa—sarcoma	0.000292	0.00145	CcSEcCtD
Sulindac—Dermatitis—Thiotepa—sarcoma	0.000292	0.00145	CcSEcCtD
Sulindac—Headache—Thiotepa—sarcoma	0.00029	0.00144	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00029	0.00144	CcSEcCtD
Sulindac—Rash—Dactinomycin—sarcoma	0.00029	0.00144	CcSEcCtD
Sulindac—Decreased appetite—Etoposide—sarcoma	0.000289	0.00143	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—sarcoma	0.000288	0.00143	CcSEcCtD
Sulindac—Renal failure—Epirubicin—sarcoma	0.000287	0.00142	CcSEcCtD
Sulindac—Asthenia—Mitoxantrone—sarcoma	0.000287	0.00142	CcSEcCtD
Sulindac—Fatigue—Etoposide—sarcoma	0.000287	0.00142	CcSEcCtD
Sulindac—Neuropathy peripheral—Epirubicin—sarcoma	0.000287	0.00142	CcSEcCtD
Sulindac—Jaundice—Epirubicin—sarcoma	0.000285	0.00141	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—sarcoma	0.000285	0.00141	CcSEcCtD
Sulindac—Constipation—Etoposide—sarcoma	0.000284	0.00141	CcSEcCtD
Sulindac—Conjunctivitis—Epirubicin—sarcoma	0.000284	0.00141	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—sarcoma	0.000284	0.00141	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—sarcoma	0.000284	0.00141	CcSEcCtD
Sulindac—Diarrhoea—Vincristine—sarcoma	0.000281	0.00139	CcSEcCtD
Sulindac—Sweating—Epirubicin—sarcoma	0.00028	0.00139	CcSEcCtD
Sulindac—Haematuria—Epirubicin—sarcoma	0.000279	0.00138	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—sarcoma	0.000277	0.00137	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—sarcoma	0.000276	0.00137	CcSEcCtD
Sulindac—Nausea—Thiotepa—sarcoma	0.000275	0.00136	CcSEcCtD
Sulindac—Feeling abnormal—Etoposide—sarcoma	0.000274	0.00136	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—sarcoma	0.000274	0.00136	CcSEcCtD
Sulindac—Diarrhoea—Mitoxantrone—sarcoma	0.000274	0.00136	CcSEcCtD
Sulindac—Nausea—Dactinomycin—sarcoma	0.000273	0.00135	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—sarcoma	0.000273	0.00135	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—sarcoma	0.000272	0.00135	CcSEcCtD
Sulindac—Gastrointestinal pain—Etoposide—sarcoma	0.000272	0.00135	CcSEcCtD
Sulindac—Dizziness—Vincristine—sarcoma	0.000271	0.00135	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000268	0.00133	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—sarcoma	0.000266	0.00132	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—sarcoma	0.000265	0.00131	CcSEcCtD
Sulindac—Urticaria—Etoposide—sarcoma	0.000264	0.00131	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—sarcoma	0.000264	0.00131	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—sarcoma	0.000264	0.00131	CcSEcCtD
Sulindac—Body temperature increased—Etoposide—sarcoma	0.000263	0.0013	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—sarcoma	0.000263	0.0013	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—sarcoma	0.000262	0.0013	CcSEcCtD
Sulindac—Vomiting—Vincristine—sarcoma	0.000261	0.00129	CcSEcCtD
Sulindac—PTGS1—lymph node—sarcoma	0.00026	0.00144	CbGeAlD
Sulindac—Sweating—Doxorubicin—sarcoma	0.000259	0.00129	CcSEcCtD
Sulindac—Rash—Vincristine—sarcoma	0.000259	0.00128	CcSEcCtD
Sulindac—Dermatitis—Vincristine—sarcoma	0.000259	0.00128	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—sarcoma	0.000258	0.00128	CcSEcCtD
Sulindac—Headache—Vincristine—sarcoma	0.000257	0.00128	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—sarcoma	0.000255	0.00126	CcSEcCtD
Sulindac—Vomiting—Mitoxantrone—sarcoma	0.000254	0.00126	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—sarcoma	0.000253	0.00125	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—sarcoma	0.000252	0.00125	CcSEcCtD
Sulindac—Rash—Mitoxantrone—sarcoma	0.000252	0.00125	CcSEcCtD
Sulindac—Dermatitis—Mitoxantrone—sarcoma	0.000252	0.00125	CcSEcCtD
Sulindac—Headache—Mitoxantrone—sarcoma	0.00025	0.00124	CcSEcCtD
Sulindac—PTGS2—lymph node—sarcoma	0.000248	0.00138	CbGeAlD
Sulindac—Erythema multiforme—Epirubicin—sarcoma	0.000248	0.00123	CcSEcCtD
Sulindac—Hypersensitivity—Etoposide—sarcoma	0.000245	0.00121	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—sarcoma	0.000245	0.00121	CcSEcCtD
Sulindac—Nausea—Vincristine—sarcoma	0.000244	0.00121	CcSEcCtD
Sulindac—Flushing—Epirubicin—sarcoma	0.000244	0.00121	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—sarcoma	0.000243	0.0012	CcSEcCtD
Sulindac—Asthenia—Etoposide—sarcoma	0.000239	0.00118	CcSEcCtD
Sulindac—Nausea—Mitoxantrone—sarcoma	0.000237	0.00118	CcSEcCtD
Sulindac—Chills—Epirubicin—sarcoma	0.000235	0.00117	CcSEcCtD
Sulindac—Pruritus—Etoposide—sarcoma	0.000235	0.00117	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—sarcoma	0.000234	0.00116	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—sarcoma	0.000234	0.00116	CcSEcCtD
Sulindac—Alopecia—Epirubicin—sarcoma	0.000232	0.00115	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—sarcoma	0.00023	0.00114	CcSEcCtD
Sulindac—Diarrhoea—Etoposide—sarcoma	0.000228	0.00113	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—sarcoma	0.000226	0.00112	CcSEcCtD
Sulindac—Flushing—Doxorubicin—sarcoma	0.000225	0.00112	CcSEcCtD
Sulindac—Flatulence—Epirubicin—sarcoma	0.000225	0.00112	CcSEcCtD
Sulindac—Tension—Epirubicin—sarcoma	0.000224	0.00111	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—sarcoma	0.000224	0.00111	CcSEcCtD
Sulindac—Nervousness—Epirubicin—sarcoma	0.000222	0.0011	CcSEcCtD
Sulindac—Dizziness—Etoposide—sarcoma	0.00022	0.00109	CcSEcCtD
Sulindac—Chills—Doxorubicin—sarcoma	0.000218	0.00108	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—sarcoma	0.000217	0.00108	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—sarcoma	0.000215	0.00107	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—sarcoma	0.000215	0.00106	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—sarcoma	0.000212	0.00105	CcSEcCtD
Sulindac—Vomiting—Etoposide—sarcoma	0.000211	0.00105	CcSEcCtD
Sulindac—Anaemia—Epirubicin—sarcoma	0.000211	0.00105	CcSEcCtD
Sulindac—Rash—Etoposide—sarcoma	0.00021	0.00104	CcSEcCtD
Sulindac—Dermatitis—Etoposide—sarcoma	0.00021	0.00104	CcSEcCtD
Sulindac—Headache—Etoposide—sarcoma	0.000208	0.00103	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—sarcoma	0.000208	0.00103	CcSEcCtD
Sulindac—Tension—Doxorubicin—sarcoma	0.000207	0.00103	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—sarcoma	0.000207	0.00103	CcSEcCtD
Sulindac—Malaise—Epirubicin—sarcoma	0.000206	0.00102	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—sarcoma	0.000205	0.00102	CcSEcCtD
Sulindac—Vertigo—Epirubicin—sarcoma	0.000205	0.00102	CcSEcCtD
Sulindac—Syncope—Epirubicin—sarcoma	0.000205	0.00102	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—sarcoma	0.000204	0.00101	CcSEcCtD
Sulindac—Palpitations—Epirubicin—sarcoma	0.000202	0.001	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—sarcoma	0.000201	0.000995	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—sarcoma	0.000199	0.000988	CcSEcCtD
Sulindac—Convulsion—Epirubicin—sarcoma	0.000198	0.000981	CcSEcCtD
Sulindac—Nausea—Etoposide—sarcoma	0.000198	0.000979	CcSEcCtD
Sulindac—Hypertension—Epirubicin—sarcoma	0.000197	0.000978	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—sarcoma	0.000196	0.000972	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—sarcoma	0.000195	0.000969	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—sarcoma	0.000194	0.000964	CcSEcCtD
Sulindac—Chest pain—Epirubicin—sarcoma	0.000194	0.000964	CcSEcCtD
Sulindac—Myalgia—Epirubicin—sarcoma	0.000194	0.000964	CcSEcCtD
Sulindac—Discomfort—Epirubicin—sarcoma	0.000192	0.000953	CcSEcCtD
Sulindac—Malaise—Doxorubicin—sarcoma	0.000191	0.000945	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—sarcoma	0.00019	0.000941	CcSEcCtD
Sulindac—Syncope—Doxorubicin—sarcoma	0.00019	0.00094	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—sarcoma	0.000189	0.000938	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—sarcoma	0.000187	0.000926	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—sarcoma	0.000186	0.000924	CcSEcCtD
Sulindac—Oedema—Epirubicin—sarcoma	0.000186	0.000924	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—sarcoma	0.000186	0.000921	CcSEcCtD
Sulindac—Shock—Epirubicin—sarcoma	0.000183	0.000909	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—sarcoma	0.000183	0.000908	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—sarcoma	0.000183	0.000905	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—sarcoma	0.000182	0.000905	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—sarcoma	0.000182	0.000902	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—sarcoma	0.00018	0.000894	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—sarcoma	0.00018	0.000892	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—sarcoma	0.00018	0.000892	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—sarcoma	0.00018	0.000892	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—sarcoma	0.000178	0.000881	CcSEcCtD
Sulindac—Anorexia—Epirubicin—sarcoma	0.000178	0.000881	CcSEcCtD
Sulindac—Hypotension—Epirubicin—sarcoma	0.000174	0.000864	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—sarcoma	0.000172	0.000855	CcSEcCtD
Sulindac—Oedema—Doxorubicin—sarcoma	0.000172	0.000855	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00017	0.000842	CcSEcCtD
Sulindac—Shock—Doxorubicin—sarcoma	0.00017	0.000841	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—sarcoma	0.000169	0.000837	CcSEcCtD
Sulindac—Insomnia—Epirubicin—sarcoma	0.000169	0.000836	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—sarcoma	0.000168	0.000835	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—sarcoma	0.000167	0.00083	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—sarcoma	0.000167	0.000827	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—sarcoma	0.000166	0.000824	CcSEcCtD
Sulindac—Somnolence—Epirubicin—sarcoma	0.000166	0.000822	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—sarcoma	0.000164	0.000815	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—sarcoma	0.000164	0.000814	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—sarcoma	0.000162	0.000803	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—sarcoma	0.000161	0.000799	CcSEcCtD
Sulindac—Fatigue—Epirubicin—sarcoma	0.000161	0.000797	CcSEcCtD
Sulindac—Constipation—Epirubicin—sarcoma	0.000159	0.00079	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000157	0.000779	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—sarcoma	0.000156	0.000774	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—sarcoma	0.000155	0.000768	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—sarcoma	0.000154	0.000762	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—sarcoma	0.000154	0.000762	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—sarcoma	0.000153	0.00076	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—sarcoma	0.000152	0.000756	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—sarcoma	0.000152	0.000753	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—sarcoma	0.00015	0.000743	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—sarcoma	0.000149	0.000737	CcSEcCtD
Sulindac—Urticaria—Epirubicin—sarcoma	0.000148	0.000734	CcSEcCtD
Sulindac—Constipation—Doxorubicin—sarcoma	0.000148	0.000731	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—sarcoma	0.000147	0.000731	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—sarcoma	0.000142	0.000705	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—sarcoma	0.000141	0.000699	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—sarcoma	0.000137	0.000681	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—sarcoma	0.000137	0.000679	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—sarcoma	0.000136	0.000676	CcSEcCtD
Sulindac—Asthenia—Epirubicin—sarcoma	0.000134	0.000663	CcSEcCtD
Sulindac—Pruritus—Epirubicin—sarcoma	0.000132	0.000654	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—sarcoma	0.000128	0.000632	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—sarcoma	0.000127	0.00063	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—sarcoma	0.000124	0.000614	CcSEcCtD
Sulindac—Dizziness—Epirubicin—sarcoma	0.000123	0.000611	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—sarcoma	0.000122	0.000605	CcSEcCtD
Sulindac—Vomiting—Epirubicin—sarcoma	0.000119	0.000588	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—sarcoma	0.000118	0.000585	CcSEcCtD
Sulindac—Rash—Epirubicin—sarcoma	0.000118	0.000583	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—sarcoma	0.000117	0.000582	CcSEcCtD
Sulindac—Headache—Epirubicin—sarcoma	0.000117	0.000579	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—sarcoma	0.000114	0.000566	CcSEcCtD
Sulindac—Nausea—Epirubicin—sarcoma	0.000111	0.000549	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—sarcoma	0.00011	0.000544	CcSEcCtD
Sulindac—Rash—Doxorubicin—sarcoma	0.000109	0.000539	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—sarcoma	0.000109	0.000539	CcSEcCtD
Sulindac—Headache—Doxorubicin—sarcoma	0.000108	0.000536	CcSEcCtD
Sulindac—Nausea—Doxorubicin—sarcoma	0.000102	0.000508	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR—EGFR—sarcoma	8.17e-05	0.00032	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	8.16e-05	0.00032	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	8.15e-05	0.00032	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	8.15e-05	0.00032	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—KRAS—sarcoma	8.12e-05	0.000318	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—EGFR—sarcoma	8.09e-05	0.000317	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—EGFR—sarcoma	8.06e-05	0.000316	CbGpPWpGaD
Sulindac—MAPK3—Disease—NPM1—sarcoma	8.05e-05	0.000316	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	8.01e-05	0.000314	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—HRAS—sarcoma	7.94e-05	0.000311	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.93e-05	0.000311	CbGpPWpGaD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	7.92e-05	0.000311	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—SRC—sarcoma	7.87e-05	0.000309	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—FOXO1—sarcoma	7.81e-05	0.000306	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KIT—sarcoma	7.81e-05	0.000306	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—NRAS—sarcoma	7.81e-05	0.000306	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—HRAS—sarcoma	7.8e-05	0.000306	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PDGFRB—sarcoma	7.79e-05	0.000306	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—KRAS—sarcoma	7.78e-05	0.000305	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	7.78e-05	0.000305	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—KRAS—sarcoma	7.78e-05	0.000305	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	7.75e-05	0.000304	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—sarcoma	7.74e-05	0.000304	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—KRAS—sarcoma	7.72e-05	0.000302	CbGpPWpGaD
Sulindac—PPARD—Generic Transcription Pathway—MYC—sarcoma	7.71e-05	0.000302	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	7.7e-05	0.000302	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PDGFRA—sarcoma	7.67e-05	0.000301	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—VEGFA—sarcoma	7.67e-05	0.000301	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—KRAS—sarcoma	7.65e-05	0.0003	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—KRAS—sarcoma	7.61e-05	0.000298	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—JUN—sarcoma	7.61e-05	0.000298	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—HRAS—sarcoma	7.59e-05	0.000298	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFC—sarcoma	7.48e-05	0.000293	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—HRAS—sarcoma	7.47e-05	0.000293	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL2—sarcoma	7.47e-05	0.000293	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CREB1—sarcoma	7.43e-05	0.000291	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—sarcoma	7.33e-05	0.000287	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	7.32e-05	0.000287	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KDR—sarcoma	7.31e-05	0.000287	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	7.3e-05	0.000286	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—sarcoma	7.21e-05	0.000283	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—HRAS—sarcoma	7.17e-05	0.000281	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	7.14e-05	0.00028	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—HRAS—sarcoma	7.14e-05	0.00028	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—EGFR—sarcoma	7.11e-05	0.000279	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—HRAS—sarcoma	7.1e-05	0.000278	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—HRAS—sarcoma	7.07e-05	0.000277	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	7.05e-05	0.000277	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—HRAS—sarcoma	7.03e-05	0.000276	CbGpPWpGaD
Sulindac—MAPK3—Disease—ENO2—sarcoma	6.97e-05	0.000273	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MYC—sarcoma	6.93e-05	0.000272	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	6.89e-05	0.00027	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—EGFR—sarcoma	6.78e-05	0.000266	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	6.75e-05	0.000265	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCR4—sarcoma	6.74e-05	0.000264	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—KRAS—sarcoma	6.72e-05	0.000263	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	6.66e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—VEGFA—sarcoma	6.65e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—sarcoma	6.65e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—HRAS—sarcoma	6.62e-05	0.000259	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HRAS—sarcoma	6.62e-05	0.000259	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	6.62e-05	0.000259	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—HRAS—sarcoma	6.56e-05	0.000257	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTPRC—sarcoma	6.55e-05	0.000257	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	6.54e-05	0.000257	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	6.51e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—HRAS—sarcoma	6.5e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—HRAS—sarcoma	6.47e-05	0.000254	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CREB1—sarcoma	6.41e-05	0.000251	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PLCG1—sarcoma	6.41e-05	0.000251	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—SRC—sarcoma	6.4e-05	0.000251	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NRAS—sarcoma	6.27e-05	0.000246	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TLE1—sarcoma	6.25e-05	0.000245	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—NRAS—sarcoma	6.16e-05	0.000242	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MDM2—sarcoma	6.15e-05	0.000241	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ATF1—sarcoma	6.09e-05	0.000239	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP2—sarcoma	5.97e-05	0.000234	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KIT—sarcoma	5.95e-05	0.000233	CbGpPWpGaD
Sulindac—MAPK3—Disease—PLCG1—sarcoma	5.92e-05	0.000232	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PLCG1—sarcoma	5.88e-05	0.000231	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	5.88e-05	0.00023	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	5.86e-05	0.00023	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	5.86e-05	0.00023	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	5.82e-05	0.000228	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—SRC—sarcoma	5.8e-05	0.000227	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRAS—sarcoma	5.71e-05	0.000224	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—sarcoma	5.69e-05	0.000223	CbGpPWpGaD
Sulindac—MAPK3—Disease—CXCR4—sarcoma	5.68e-05	0.000223	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	5.66e-05	0.000222	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CREB1—sarcoma	5.66e-05	0.000222	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—VEGFA—sarcoma	5.65e-05	0.000221	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—EGFR—sarcoma	5.61e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—NRAS—sarcoma	5.58e-05	0.000219	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL2—sarcoma	5.49e-05	0.000215	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—KRAS—sarcoma	5.39e-05	0.000211	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCND1—sarcoma	5.36e-05	0.00021	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—JUN—sarcoma	5.34e-05	0.00021	CbGpPWpGaD
Sulindac—PTGS2—Disease—TLE1—sarcoma	5.31e-05	0.000208	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CTNNB1—sarcoma	5.3e-05	0.000208	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KRAS—sarcoma	5.3e-05	0.000208	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFC—sarcoma	5.27e-05	0.000207	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	5.26e-05	0.000206	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	5.12e-05	0.000201	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—EGFR—sarcoma	5.08e-05	0.000199	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—sarcoma	5.02e-05	0.000197	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MDM2—sarcoma	4.91e-05	0.000193	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—KRAS—sarcoma	4.8e-05	0.000188	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—SRC—sarcoma	4.79e-05	0.000188	CbGpPWpGaD
Sulindac—PTGS2—Disease—NPM1—sarcoma	4.79e-05	0.000188	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CCND1—sarcoma	4.78e-05	0.000188	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	4.71e-05	0.000185	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MDM2—sarcoma	4.69e-05	0.000184	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—sarcoma	4.67e-05	0.000183	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IL2—sarcoma	4.65e-05	0.000182	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NRAS—sarcoma	4.61e-05	0.000181	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	4.61e-05	0.000181	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—sarcoma	4.58e-05	0.00018	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CTNNB1—sarcoma	4.58e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FOXO1—sarcoma	4.55e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PDGFRB—sarcoma	4.54e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—sarcoma	4.51e-05	0.000177	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PDGFRA—sarcoma	4.47e-05	0.000175	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ENO2—sarcoma	4.38e-05	0.000172	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	4.36e-05	0.000171	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—HBA1—sarcoma	4.35e-05	0.00017	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	4.34e-05	0.00017	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MYC—sarcoma	4.3e-05	0.000168	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CCND1—sarcoma	4.28e-05	0.000168	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FLT1—sarcoma	4.22e-05	0.000165	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EGFR—sarcoma	4.2e-05	0.000165	CbGpPWpGaD
Sulindac—MAPK3—Disease—FOXO1—sarcoma	4.2e-05	0.000165	CbGpPWpGaD
Sulindac—MAPK3—Disease—PDGFRB—sarcoma	4.19e-05	0.000164	CbGpPWpGaD
Sulindac—PTGS2—Disease—ENO2—sarcoma	4.15e-05	0.000163	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PLCG1—sarcoma	4.14e-05	0.000162	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—SRC—sarcoma	4.14e-05	0.000162	CbGpPWpGaD
Sulindac—MAPK3—Disease—PDGFRA—sarcoma	4.13e-05	0.000162	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—sarcoma	4.08e-05	0.00016	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—JUN—sarcoma	4.07e-05	0.00016	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—SRC—sarcoma	4.06e-05	0.000159	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CTNNB1—sarcoma	4.04e-05	0.000158	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—sarcoma	4.03e-05	0.000158	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCR4—sarcoma	3.98e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NRAS—sarcoma	3.98e-05	0.000156	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KRAS—sarcoma	3.97e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—sarcoma	3.95e-05	0.000155	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ATF1—sarcoma	3.94e-05	0.000154	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NRAS—sarcoma	3.9e-05	0.000153	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	3.87e-05	0.000152	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MYC—sarcoma	3.84e-05	0.00015	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	3.79e-05	0.000148	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MYC—sarcoma	3.71e-05	0.000146	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PLCG1—sarcoma	3.71e-05	0.000146	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	3.69e-05	0.000145	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—SRC—sarcoma	3.65e-05	0.000143	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EGFR—sarcoma	3.63e-05	0.000142	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CREB1—sarcoma	3.61e-05	0.000142	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—sarcoma	3.53e-05	0.000138	CbGpPWpGaD
Sulindac—PTGS2—Disease—PLCG1—sarcoma	3.52e-05	0.000138	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NRAS—sarcoma	3.51e-05	0.000138	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ENO2—sarcoma	3.47e-05	0.000136	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KIT—sarcoma	3.46e-05	0.000136	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HBA1—sarcoma	3.45e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MYC—sarcoma	3.43e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—sarcoma	3.42e-05	0.000134	CbGpPWpGaD
Sulindac—PTGS2—Disease—CXCR4—sarcoma	3.38e-05	0.000133	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—sarcoma	3.37e-05	0.000132	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—sarcoma	3.36e-05	0.000132	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CREB1—sarcoma	3.3e-05	0.000129	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EGFR—sarcoma	3.2e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Disease—KIT—sarcoma	3.2e-05	0.000125	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1R—sarcoma	3.09e-05	0.000121	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ENO2—sarcoma	3.08e-05	0.000121	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HBA1—sarcoma	3.06e-05	0.00012	CbGpPWpGaD
Sulindac—MAPK3—Disease—CREB1—sarcoma	3.05e-05	0.000119	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—sarcoma	3.02e-05	0.000119	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—sarcoma	2.99e-05	0.000117	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PLCG1—sarcoma	2.95e-05	0.000116	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FOXO1—sarcoma	2.94e-05	0.000115	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PDGFRB—sarcoma	2.93e-05	0.000115	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—sarcoma	2.91e-05	0.000114	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PDGFRA—sarcoma	2.89e-05	0.000113	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—sarcoma	2.86e-05	0.000112	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—sarcoma	2.82e-05	0.00011	CbGpPWpGaD
Sulindac—ALB—Metabolism—ENO2—sarcoma	2.81e-05	0.00011	CbGpPWpGaD
Sulindac—ALB—Metabolism—HBA1—sarcoma	2.79e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MDM2—sarcoma	2.73e-05	0.000107	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—sarcoma	2.67e-05	0.000105	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PLCG1—sarcoma	2.62e-05	0.000103	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—sarcoma	2.57e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Disease—MDM2—sarcoma	2.52e-05	9.88e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FOXO1—sarcoma	2.5e-05	9.79e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PDGFRB—sarcoma	2.49e-05	9.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PDGFRA—sarcoma	2.45e-05	9.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—sarcoma	2.44e-05	9.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KDR—sarcoma	2.43e-05	9.54e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PLCG1—sarcoma	2.38e-05	9.35e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—JUN—sarcoma	2.37e-05	9.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTNNB1—sarcoma	2.35e-05	9.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KIT—sarcoma	2.24e-05	8.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—sarcoma	2.24e-05	8.78e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—sarcoma	2.24e-05	8.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—sarcoma	2.17e-05	8.52e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CREB1—sarcoma	2.13e-05	8.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SRC—sarcoma	2.13e-05	8.34e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—sarcoma	2.05e-05	8.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—sarcoma	2.04e-05	8e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO2—sarcoma	1.97e-05	7.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SRC—sarcoma	1.96e-05	7.7e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HBA1—sarcoma	1.95e-05	7.66e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SRC—sarcoma	1.95e-05	7.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—sarcoma	1.93e-05	7.56e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KIT—sarcoma	1.9e-05	7.46e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—sarcoma	1.9e-05	7.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—sarcoma	1.9e-05	7.43e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—sarcoma	1.89e-05	7.41e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—sarcoma	1.88e-05	7.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—sarcoma	1.86e-05	7.31e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CREB1—sarcoma	1.81e-05	7.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MDM2—sarcoma	1.76e-05	6.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—sarcoma	1.76e-05	6.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—sarcoma	1.76e-05	6.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—sarcoma	1.72e-05	6.75e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLCG1—sarcoma	1.67e-05	6.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—sarcoma	1.64e-05	6.43e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—sarcoma	1.63e-05	6.38e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—sarcoma	1.62e-05	6.34e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—sarcoma	1.58e-05	6.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—sarcoma	1.54e-05	6.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—sarcoma	1.53e-05	6.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—sarcoma	1.52e-05	5.97e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MDM2—sarcoma	1.5e-05	5.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—sarcoma	1.5e-05	5.87e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—sarcoma	1.44e-05	5.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—sarcoma	1.38e-05	5.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SRC—sarcoma	1.38e-05	5.39e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—sarcoma	1.37e-05	5.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—sarcoma	1.34e-05	5.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—sarcoma	1.32e-05	5.19e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—sarcoma	1.29e-05	5.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—sarcoma	1.23e-05	4.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—sarcoma	1.21e-05	4.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SRC—sarcoma	1.17e-05	4.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—sarcoma	1.14e-05	4.47e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—sarcoma	1.12e-05	4.41e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—sarcoma	1.05e-05	4.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—sarcoma	1.02e-05	4.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—sarcoma	1.01e-05	3.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—sarcoma	9.68e-06	3.8e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—sarcoma	9.67e-06	3.79e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—sarcoma	8.22e-06	3.22e-05	CbGpPWpGaD
